AQ4
[6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE
Find entries where: AQ4
is present as a standalone ligand in 3 entries
Chemical Component Summary | |
---|---|
Name | [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE |
Synonyms | ERLOTINIB |
Identifiers | N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine |
Formula | C22 H23 N3 O4 |
Molecular Weight | 393.436 |
Type | NON-POLYMER |
Isomeric SMILES | COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C |
InChI | InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25) |
InChIKey | AAKJLRGGTJKAMG-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 52 |
Chiral Atom Count | 0 |
Bond Count | 54 |
Aromatic Bond Count | 17 |
Drug Info: DrugBank
DrugBank ID | DB00530 |
---|---|
Name | Erlotinib |
Groups |
|
Description | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders. |
Synonyms |
|
Brand Names |
|
Indication | Erlotinib is indicated for: - The treatment of metastatic non-small cell lung cancer (NSCLC) with tumors showing epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations [FDA label]. - In combination with first-line treatment for patients diagnosed with locally advanced, unresectable or metastatic pancreatic cancer [FDA label]. The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy. [FDA label] |
Categories |
|
ATC-Code | L01EB02 |
CAS number | 183321-74-6 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Nuclear receptor subfamily 1 group I member 2 | MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATG... | unknown | agonist |
Epidermal growth factor receptor | MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLS... | unknown | antagonist |
Cytochrome P450 3A4 | MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI... | unknown | substrate,inhibitor |
Cytochrome P450 3A5 | MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV... | unknown | substrate |
Cytochrome P450 1A2 | MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL... | unknown | substrate |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL553 |
PubChem | 176870 |
ChEMBL | CHEMBL553 |
ChEBI | CHEBI:114785 |
CCDC/CSD | DULKAX01, OMEJUN01, OMEKOI, OMEKIC, OMEKEY, OMEJUN |